ARPA-H Funds Consortium to Develop Gene-Editing Treatments for Rare Childhood Epilepsies

Rare Daily Staff

The Advanced Research Projects Agency for Health has awarded a coalition of scientists, doctors, and patient advocacy groups up to $34.5 million to develop gene-editing treatments for rare and severe forms of childhood epilepsy.

The project, led by the Broad Institute in collaboration with 11 partner organizations, aims to move a potential therapy into human testing within three years. The funding comes from the Advanced Research Projects Agency for Health (ARPA-H), a federal initiative designed to accelerate high-risk, high-impact medical breakthroughs.

If successful, the platform could extend beyond epilepsy to other genetic brain disorders, offering a scalable way to bring personalized gene-editing therapies to patients who have long been overlooked.

The effort targets a group of conditions known as developmental and epileptic encephalopathies, which affect more than three million children worldwide. These disorders are caused by mutations in more than 400 different genes, often leaving families with few or no treatment options. Because any single mutation may affect only a small number of patients, traditional drug development has struggled to address them.

To overcome this challenge, the new initiative, known as the Pediatric Epilepsies and Rare CNS (PERC) Gene Editing Platform, seeks to create a shared system for developing therapies across multiple diseases. By standardizing manufacturing, regulatory pathways, and clinical infrastructure, researchers hope to make it faster and more feasible to treat ultra-rare conditions.

The platform will initially focus on two severe disorders: Alternating Hemiplegia of Childhood (AHC), which can cause episodes of paralysis and seizures, and Dravet syndrome, a life-threatening epilepsy that begins in infancy.

At the core of the approach is gene editing, a technology that can directly correct disease-causing DNA mutations. The team plans to use advanced tools such as base editing and prime editing, which allow precise changes to genetic code, combined with a newly engineered delivery system designed to reach the brain.

Delivering therapies to the brain has long been a major hurdle. The group is using an experimental viral vector that can cross the blood-brain barrier after a simple intravenous infusion, potentially eliminating the need for invasive brain or spinal procedures.

Results from animal models of both targeted diseases are encouraging. Scientists have demonstrated that the gene-editing approach can restore normal function. The delivery system has also shown promising safety data in preclinical studies, with initial human data expected later this year.

The broader collaboration includes academic institutions, biotechnology companies, clinical trial organizations, and patient advocacy groups, reflecting what organizers describe as a new model for tackling rare diseases.